Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells.

Cancer Research
Aparna RaoWalter J Storkus

Abstract

Ineffective recognition of tumor cells by CD8+ T cells is a limitation of cancer immunotherapy. Therefore, treatment regimens that coordinately promote enhanced antitumor CD8+ T-cell activation, delivery, and target cell recognition should yield greater clinical benefit. Using an MCA205 sarcoma model, we show that in vitro treatment of tumor cells with the HSP90 inhibitor 17-DMAG results in the transient (proteasome-dependent) degradation of the HSP90 client protein EphA2 and the subsequent increased recognition of tumor cells by Type-1 anti-EphA2 CD8+ T cells. In vivo administration of 17-DMAG to tumor-bearing mice led to slowed tumor growth, enhanced/prolonged recognition of tumor cells by anti-EphA2 CD8+ T cells, reduced levels of myeloid-derived suppressor cells and regulatory T cells in the tumor microenvironment, and activation of tumor-associated vascular endothelial cells in association with elevated levels of Type-1 tumor-infiltrating lymphocytes. When combined with EphA2-specific active vaccination or the adoptive transfer of EphA2-specific CD8+ T cells, 17-DMAG cotreatment yielded a superior tumor therapeutic regimen that was capable of rendering animals free of disease. Taken together, our findings indicate that 17-...Continue Reading

References

Dec 15, 2000·Oncogene·D R RobinsonS F Lin
Sep 22, 2001·Endocrine-related Cancer·E ZwickA Ullrich
Dec 26, 2001·Cytokine & Growth Factor Reviews·Nikki ChengJin Chen
Mar 26, 2003·Clinical & Experimental Metastasis·Michael S Kinch, Kelly Carles-Kinch
Feb 12, 2004·Cancer Research·Pawel DobrzanskiBruce Ruggeri
Jul 2, 2004·The EMBO Journal·Kristi G BacheHarald Stenmark
Nov 25, 2004·Cytokine & Growth Factor Reviews·Hanna SurawskaRavi Salgia
Jan 27, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christopher J HerremWalter J Storkus
Sep 22, 2005·Nature Reviews. Cancer·Luke Whitesell, Susan L Lindquist
Sep 2, 2006·Science·Richard A MorganSteven A Rosenberg
Nov 15, 2006·Current Cancer Drug Targets·Mehmet Alper ArslanHuveyda Basaga
Mar 17, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Brenda J WeigelPeter C Adamson
Jun 6, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jooeun BaeNikhil C Munshi
Mar 21, 2008·Nature Reviews. Cancer·Steven A RosenbergMark E Dudley
Nov 20, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Amy K WesaWalter J Storkus
Dec 17, 2008·Molecular Cancer Research : MCR·Jill Wykosky, Waldemar Debinski
Aug 28, 2009·Radiation Research·Juliann G KiangNeil G Agravante
Dec 1, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Shivaani KummarAnthony J Murgo
Feb 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ramesh K RamanathanChandra P Belani
Sep 8, 2010·The New England Journal of Medicine·Philip W KantoffUNKNOWN IMPACT Study Investigators
Dec 30, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Xi ZhaoWalter J Storkus
Feb 1, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Simon PaceyIan Judson
Jul 1, 2011·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Chen-Nen ChangWen-Kuang Yang
Oct 18, 2011·European Urology·Steven JoniauSusanne Osanto
Nov 16, 2011·Breast Cancer Research and Treatment·Elaina M GartnerPatricia M Lorusso
Dec 2, 2011·Journal of Biomedicine & Biotechnology·Adham S BearAaron E Foster

❮ Previous
Next ❯

Citations

Jan 1, 2013·Journal for Immunotherapy of Cancer·Robert WesolowskiWilliam E Carson
Dec 18, 2012·Oncoimmunology·Aparna RaoWalter J Storkus
Dec 30, 2014·Frontiers in Oncology·Kim De VeirmanJo A Van Ginderachter
Oct 17, 2017·Archivum Immunologiae Et Therapiae Experimentalis·Maria Ibáñez-VeaGrazyna Kochan
Sep 8, 2017·Nature Communications·Rina M MbofungPatrick Hwu
Feb 2, 2019·Nature Reviews. Clinical Oncology·Yosuke TogashiHiroyoshi Nishikawa
Oct 24, 2019·Journal of Hematology & Oncology·Meng LvXiao-Jun Huang
Jan 28, 2021·Cell Death & Disease·Christopher E EyermannEvguenia M Alexandrova
Apr 6, 2021·Frontiers in Immunology·Zarema AlbakovaAlexander Sapozhnikov
Aug 25, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Shuxian YangLi Cao
Mar 31, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Hassan MellatyarNosratollah Zarghami

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.